about
Advantages and Challenges of Dried Blood Spot Analysis by Mass Spectrometry Across the Total Testing ProcessBioluminescent Antibodies for Point-of-Care Diagnostics.Nails are a potential alternative matrix to hair for drug analysis in general unknown screenings by liquid-chromatography quadrupole time-of-flight mass spectrometry.Silica coated paper substrate for paper-spray analysis of therapeutic drugs in dried blood spots.Paper spray ionization devices for direct, biomedical analysis using mass spectrometry.Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements.Field-assisted paper spray mass spectrometry for the quantitative evaluation of imatinib levels in plasma.Therapeutic drug monitoring for tomorrow.Emerging liquid chromatography-mass spectrometry technologies improving dried blood spot analysis.Bioluminescent sensor proteins for point-of-care therapeutic drug monitoring.Mass spectrometry in the pharmacokinetic studies of anticancer natural products.Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effect.Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples.Preparation of novel deuterated cyclosporin A standards for quantitative LC-MS analysis.Field-assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma.Analysis of in vivo absorption of didanosine tablets in male adult dogs by HPLC.Esterase inhibitors as ester-containing drug stabilizers and their hydrolytic products: potential contributors to the matrix effects on bioanalysis by liquid chromatography/tandem mass spectrometry.Rapid LC-MS/MS quantification of the major benzodiazepines and their metabolites on dried blood spots using a simple and cost-effective sample pretreatment.
P2860
Q29109543-0061AD6C-BADF-4747-93F0-8D5306112E84Q33845719-0D8C0D54-DDA8-4EA1-8C69-CCE5829DD84EQ35209034-21B3804C-BAC1-4995-9592-F345D88AA470Q35690824-21FD029A-ECD8-4079-8061-203D593AF749Q35763392-B3915A4C-25D8-41EE-9643-192D746AB5BCQ36033002-DBA00A0F-FF80-419E-8BA1-CD4CCB19D8B1Q36203262-24DC7651-8E19-4B1C-ADB8-A3DCA43C9ECBQ38103768-F2E887A7-FB85-4B17-BD8D-9CF074DC23A5Q38201783-41509669-91D4-4A1D-B168-535753D0B6BDQ38397327-56510442-B66D-4674-8988-62E91368C61EQ38568180-1EF0A211-2353-4E86-9219-748809A7909EQ40122652-429CBC47-BD88-4DF1-8CDA-95C5F222EA4EQ41144825-E0B73791-F75C-4F86-B60F-E0358F116BACQ46072595-D9103392-3445-4167-A77E-2F58416A05E2Q48134660-0E2F2AFE-BD96-4C41-AD56-D1AC72B6166CQ48174042-6A954512-EB3C-46A9-BAE4-078E8E07ED73Q49165327-873A053B-05EF-4600-868F-08B458F1A6D2Q52737161-738308CA-FE32-4E79-92B1-9201E31F0C0FQ53128171-DFFA3682-8D64-448D-B95C-7379C207C777
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Current role of LC-MS in therapeutic drug monitoring.
@en
type
label
Current role of LC-MS in therapeutic drug monitoring.
@en
prefLabel
Current role of LC-MS in therapeutic drug monitoring.
@en
P2860
P1476
Current role of LC-MS in therapeutic drug monitoring.
@en
P2093
Franck Saint-Marcoux
François-Ludovic Sauvage
P2860
P2888
P304
P356
10.1007/S00216-007-1320-1
P407
P577
2007-05-23T00:00:00Z